Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Aiforia launches new AI platform

Aiforia Technologies

Translation: Original published in Finnish on 12/18/2025 at 8:20 am EET.

Aiforia announced on Wednesday the launch of a new generation AI platform that utilizes Vision Transformer technology. The new technology promises to accelerate the development of AI models and improve their performance, supporting the expansion of the company's product portfolio. The news has no direct impact on our forecasts, but we view the increased efficiency in product development positively, as it partly mitigates risks related to the company's innovation capabilities after cost cuts and supports its long-term competitiveness.

The new Foundation Engine solution enhances model development

Aiforia announced on Wednesday that it is expanding its AI platform with a new solution called Foundation Engine, which is based on the Vision Transformer architecture. According to the company, the new solution combines so-called foundation models, pre-trained on extensive image datasets, with task-specific annotations made by pathologists. Aiforia highlights that the key benefits of the technology are the acceleration of AI model development and the improved generalizability of models to different image datasets. The new technology will be deployed in Aiforia's own product development and will also be integrated into the Aiforia Create development tool available to customers.

The company referred to the benefits of the expansion in its own product development earlier in the fall, so the launch does not come as a particular surprise or put pressure on forecast changes. In any case, the acceleration of model development supports the company's goals to improve its operational efficiency. Aiforia has recently focused on optimizing its cost structure and securing its path to profitability. In our view, more efficient product development through new technology mitigates the risks of cost savings to the company's innovation pace and supports the company's ability to maintain competitiveness in the long term. In addition to supporting the expansion of the product portfolio in the clinical segment, which is central to Aiforia's growth strategy, the technology also fundamentally strengthens Aiforia's product for its research customers who develop their own models on the Aiforia platform.

 

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more on company page

Key Estimate Figures2025-11-19

202425e26e
Revenue2.93.35.1
growth-%18.9 %16.4 %55.0 %
EBIT (adj.)-12.2-10.9-8.6
EBIT-% (adj.)-427.8 %-328.4 %-167.6 %
EPS (adj.)-0.41-0.39-0.28
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

So, keeping in mind the high gross margin, we could perhaps for this reason subtract one million from the 2026 cash burn estimate, and another...
yesterday
by Puutaheinää
4
Here is some further clarification regarding revenue recognition, which at least previously was a bit unclear to me. Accounts receivable have...
yesterday
by Jekkku
4
My rough estimate is that The 12/2025 additional funding, together with this year’s savings, will last until max Q4/2026. The 2025 net result...
yesterday
by Pekka
6
Inderes Aiforia Technologies Oyj – Johdon liiketoimet – Tuomas Tenkanen - Inderes Aiforia Technologies Oyj, Yhtiötiedote, Johtohenkilöiden liiketoimet...
yesterday
by Critter
27
It was reported as an acquisition, not a share reward, meaning it was bought from the exchange with their own money. I expect there will be ...
yesterday
by Jekkku
1
It was reported as an acquisition, not a share reward, meaning it was bought from the exchange with their own money.
yesterday
by Jekkku
0
It also states that negotiations for the sale of the company are not at an active stage. Siemens Healthineers will therefore not be acquiring...
yesterday
by Eituottoailmanriskiä
2
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.